AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Labetalol
Description: 10 - 20 mg IV q15 minutes PRN until systolic BP below target (max 300 mg per 24 hours)
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mg HC-ER
Description: Single dose
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30 mg HC-ER
Description: Single dose
Study NCT02197156 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg HC-ER
Description: Single dose
Study NCT03562767 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Usual care group participants will continue to receive care and follow up from their primary care providers as per the American Diabetes Association guidelines with log books, education regarding self-management strategies and appropriate referrals as needed.
Study NCT03893890 — intervention group
Intervention type: BIOLOGICAL
Intervention: Previously Treated with EN3835
Description: No treatment to be administered - Observational only
Study NCT02204761 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Proton Beam Radiation Therapy
Description: Undergo proton beam re-irradiation therapy
Study NCT00456144 — intervention group
Intervention type: DRUG
Intervention: Gonadotropin Releasing Hormone Agonist Therapy
Description: Given either for 24 months and 6 months
Study NCT01863589 — intervention group
Intervention type: DRUG
Intervention: Adefovir tablets
Description: Administered according to the prescribing information in the locally approved label by the authorities.
Study NCT00927940 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MDT-4107 Drug Eluting Stent
Description: Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
Study NCT03007888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sinemet
Description: Immediate Release Tablet containing carbidopa-levodopa flexible dosing
Study NCT03007888 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX203
Description: Extended Release capsules containing carbidopa-levodopa flexible dosing
Study NCT01658813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil and Interferon
Description: 5-Fluorouracil Interferon-alfa-2b
Study NCT05270447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage and patient education
Description: Connective tissue manipulation: The patients were informed about CTM and its mechanism of action before starting the CTM application. CTM was performed by a trained physiotherapist as the patient was in a sitting position.~Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
Study NCT05270447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Routine care and advising
Description: Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
Study NCT05270447 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Routine care and advising
Description: Routine care and advising: In-bed activities were taught and recommended to the patients in both groups. In-bed activities; rotation, sitting on the bedside, breathing exercises, range of motion exercises for upper and lower extremities. In addition, hourly walking activities were recommended after the anesthetic effect wore off.
Study NCT00528541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 200 Units at Visit 1 (Day 1)
Study NCT00528541 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: botulinum toxin type A
Description: 750 Units at Visit 1 (Day 1)
Study NCT00471614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NucleomaxX (contains uridine)
Description: Escalated doses of NucleomaxX tid
Study NCT00471614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NucleomaxX (contains uridine)
Description: Escalated doses of NucleomaxX tid
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine
Study NCT02285062 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Study NCT02858700 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP
Study NCT01845623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAB149 75 mg Concept 1
Description: QAB149 delivered via the concept 1 device.
Study NCT01845623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAB149 75 mg Epic Test Fixture
Description: QAB149 delivered via the EPIC test fixture
Study NCT01845623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo Concept 1
Description: Placebo administered via the Concept 1 device.
Study NCT01845623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Concept 1
Description: Placebo administered via the Concept 1 device.
Study NCT01845623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo EPIC Test Fixture
Description: Placebo administered via the EPIC Test Fixture.
Study NCT01845623 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo EPIC Test Fixture
Description: Placebo administered via the EPIC Test Fixture.
Study NCT02793622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy
Study NCT02793622 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy
Study NCT03337672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intravenous dexmedetomidine 0.3mcg/kg is slowly infused at 5 minutes before the end of surgery
Study NCT03337672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Intravenous dexmedetomidine 0.03mg/kg is slowly infused at 5 minutes before the end of surgery
Study NCT02589600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Description: Annual intravenous 5.0 mg
Study NCT02589600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: 800 IU daily
Study NCT02589600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: vitamin D
Description: 800 IU daily
Study NCT02589600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium
Description: approximately 1200 mg (dietary and supplement)
Study NCT02589600 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium
Description: approximately 1200 mg (dietary and supplement)
Study NCT02589600 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Annual intravenous saline placebo
Study NCT02461472 — intervention group
Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study, no intervention was performed.
Study NCT02557074 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL2
Description: IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
Study NCT02557074 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
Study NCT00403169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: drug
Study NCT03189498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64041575
Description: All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4\*250 mg tablets) on Day 1.
Study NCT05349201 — intervention group
Intervention type: OTHER
Intervention: KYMRIAH
Description: Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\]) or Pediatric and young adult patients (≤25 years of age) with B cell acute lymphoblastic leukemia (ALL) refractory, in relapse post transplant or in second or later relapse
Study NCT05349201 — intervention group
Intervention type: OTHER
Intervention: YESCARTA
Description: Patients (≥18 years of age) with (relapsed/refractory diffuse large B cell lymphoma \[R/R DLBCL\])
Study NCT02990247 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: anharmonic morphological analysis of the respiratory signals (AMARS)
Study NCT04268602 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: local anesthetic injection
Description: 1% lidocaine
Study NCT01459289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: leaflet
Study NCT01459289 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: counseling and leaflet
Study NCT01190735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine alkaloid
Description: The following intervention will be provided for six consecutive weeks:~Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed.
Study NCT02030431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Dynaloc
Study NCT02030431 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cancellous screws
Study NCT02996058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.35µg/kg /h
Description: the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
Study NCT02996058 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine 0.5µg/kg /h
Description: the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
Study NCT02916121 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: folic acid 5 mg/cap
Description: the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
Study NCT02916121 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT01908946 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
Study NCT05218954 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biomechanical analysis of risk fall
Description: Biomechanical analysis of risk fall in terms of balance
Study NCT01092832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: voriconazole
Description: Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.~Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).~Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.
Study NCT00133978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glutamine
Description: 0.35 gm/kg/day parenterally and 30 gms/day enterally
Study NCT00133978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Antioxidants
Description: 500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
Study NCT00133978 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glutamine + Antioxidants
Description: 0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
Study NCT03301948 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Balance
Description: Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
Study NCT01334333 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus - Prograf® twice daily formulation
Description: twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
Study NCT01334333 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus - Advagraf® once daily formulation
Description: once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
Study NCT03387176 — intervention group
Intervention type: OTHER
Intervention: Implementation of a gluten-free diet
Description: Patients will be placed on gluten free diet for 9-12 months.
Study NCT03127631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Nutrition
Description: Standardized advice on healthy diet practices.
Study NCT03127631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Standardized advice on exercise including strength training and resistance training exercises.
Study NCT03127631 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Smoking cessation
Description: Advice to quit smoking, if applicable, and on available aids to quit smoking,
Study NCT03127631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Statin (such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)
Description: Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydralazine
Description: 10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydralazine
Description: 10 - 20 mg IV bolus q20 min until systolic BP below target (max 240 mg per 24 hours)
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enalapril
Description: 1.25 - 2.5 mg IV bolus and then q6h PRN.
Study NCT04484350 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enalapril
Description: 1.25 - 2.5 mg IV bolus and then q6h PRN.
Study NCT01583426 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-Paclitaxel
Description: nab-Paclitaxel 125 mg/m² weekly for 12 weeks
Study NCT01583426 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m² weekly for 12 weeks
Study NCT02518555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Description: Given IM
Study NCT02518555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT00133978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
Study NCT02518555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02518555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02518555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal 13-valent Conjugate Vaccine
Description: Given IM
Study NCT02518555 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02518555 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent Influenza Vaccine
Description: Given IM
Study NCT03158402 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prehabilitation with inspiratory muscle training
Description: 3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
Study NCT04493840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shenfu Injection
Description: 80ml Shenfu Injection + 70ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Study NCT04493840 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5% Glucose Injection
Description: 150 ml 5% glucose injection, ivdrip, within 30 minutes before PCI and 1 to 5 days (once a day) after PCI (6 times in total). Drug titration time should be no less than 30 minutes.
Study NCT05428189 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Plaque Disclosing Agent
Description: A plaque disclosing agent is applied on teeth to detect plaque. Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
Study NCT05428189 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Airpolishing and ultrasonic debridement
Description: Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
Study NCT05428189 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Airpolishing and ultrasonic debridement
Description: Air-polishing will be used as main instrument for biofilm and stains removal, followed by ultrasonic scaling.
Study NCT01874678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-1/Cisplatin
Study NCT01390064 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
Study NCT01390064 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG
Description: All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
Study NCT01529801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group A
Description: Osseotite Certain Tapered with different surface roughness
Study NCT01529801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group B
Description: Osseotite Certain Tapered with different surface roughness
Study NCT01529801 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osseotite Certain Tapered Group C
Description: Osseotite Certain Tapered with different surface roughness
Study NCT05143710 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: PRES in PE or E
Description: patients diagnosed with posterior reversible encephalopathy syndrome with preeclampsia or eclampsia
Study NCT03680456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ferric carboxymaltose
Description: maximum of 750mg in U.S. is given, maximum of 1000mg in EU
Study NCT03680456 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Crystalloid
Description: an equivalent volume dose of Natriumchlorid is administered